Term
| Azidothymidine, Zidovudine class |
|
Definition
|
|
Term
|
Definition
| Azidothymidine, Zidovudine, Didanosine, Zalcitabine, Lamivudine, Stavudine, Emtricitabine, |
|
|
Term
thymidine analogue. First phosphorylated by cellular thymidine kinase
______triphosphate terminates viral dNA synthesis by RT |
|
Definition
|
|
Term
| Initial agent of choice for HIV infection w/ CD4 < 500 /mm3 |
|
Definition
|
|
Term
| combination w/ zalcitabine has shown higher survival |
|
Definition
|
|
Term
| NRTI approved for treatment of advanced HIV infection in adults and children over 6 months |
|
Definition
|
|
Term
| NRTI approved for treatment of advanced HIV infection in adults and children over 6 months INTOLERANT TO OTHER THERAPIES |
|
Definition
|
|
Term
| approved for HIV infection in combo with zidovudine in pts w/ CD4 counts <300mm3 |
|
Definition
|
|
Term
| drugs that inhibit glucuronidation (fluconazole) may increase toxicity of this drug group |
|
Definition
|
|
Term
| Bone marrow suppression (granulocytopenia and anemia) |
|
Definition
|
|
Term
| painful sensory peripheral neruopathy |
|
Definition
|
|
Term
| guanine analogue NRTI useful in HIV infections. Used in viruses rsistant to 3TC (Lamivudine) and AZT(Zidovudine) |
|
Definition
|
|
Term
| NRTIs sometimes called NtRTIs |
|
Definition
|
|
Term
| Nucleotide analogs approved for HIV as well as HBV infections |
|
Definition
|
|
Term
| activation very selective for HIV-1 (not HIV 2) virus specific reverse transcriptase |
|
Definition
|
|
Term
| NNRTIs that bind directly to a site on the viral RT that is near or distinct form the NRTIs. Do not compete with nucleoside triphosphate or require phospohrylation to be active. |
|
Definition
| Nevirapine, Delavirdine, Efavirenz |
|
|
Term
| block RNA dependent and DNA dependent DNA polymerases |
|
Definition
| Nevirapine, Delavirdine, Efavirenz |
|
|
Term
| second generation NNRTI shown t have low resistance when compared to others |
|
Definition
|
|
Term
Second generation NNRTI.
Pyrimidine analogue.
high potentcy, long half life, reduced adverse effects compared to Efavirenz |
|
Definition
|
|
Term
| non peptide PI covers HIV protease variants resistant to other PIs and has shown to lower development of resistance |
|
Definition
|
|
Term
| HIV aspartate protease inhibitor that inhibits cleavage of the polypeptide precursors that generate the structural proteins and enzymes of the virus |
|
Definition
|
|
Term
| thrombocytopenia, hyperbilirubinemia, renal damage (hydration reduces |
|
Definition
| protease inhibitors (avirs) |
|
|
Term
| Use of these drugs with Rifampin is contraindicated (see resistance within a year) |
|
Definition
| protease inhibitors (avirs) |
|
|
Term
| Protease inhibitors contraindicated w/ use of |
|
Definition
|
|
Term
| 36 amino acid peptide derived from HIV envelope glycoprotein gp41 |
|
Definition
|
|
Term
| prevents fusionof viral and cellular membranes blocking HIV 1 from entering |
|
Definition
|
|
Term
| reserved for salvage therapy for those w/ advance disease or resistance to current treatments |
|
Definition
|
|
Term
| binds to FIRST HEPTAD REPEAT in gp41 |
|
Definition
|
|
Term
| serious injection site reactions, increased bacterial infections, diarrhea and nasuea |
|
Definition
|
|
Term
| inhibits HIV entry into human cells through CCR5 co-receptor on Th cells |
|
Definition
|
|
Term
| Effective at reducing viral load in patients w/ CCR5-tropic HIV strains |
|
Definition
|
|
Term
| not effective vs. virus targeting CXCR4 co receptor (CXCR4-tropic HIV) low therapeutic vs HIV w/ dual tropism |
|
Definition
|
|
Term
| hepatotoxicity and symptoms of allergic reaction have reported |
|
Definition
|
|
Term
| new class of antiretroviral drug that inhibits INTEGRATION |
|
Definition
|
|
